ArticleBreast cancer research and treatment2025
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer.Cancer research · 2026Article
- Circulating cell-free DNA and circulating tumor DNA as a prognostic biomarker in metastatic spine disease, is there a role?Neurosurgical review · 2026Review
- Circulating DNA tumor fraction as a biomarker for advanced breast cancer.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBone metastases develop in 50-70% of patients with metastatic breast cancer (MBC), with around one-third having bone as only site of distant disease (bone-only [BO]). Standard imaging is frequently insufficient to track bone metastases. Evidence suggests that circulating tumor DNA (ctDNA) tumor fraction (TF) is prognostic in MBC. We hypothesized that TF would be detectable and prognostic for BO-MBC.
methodsMBC patients who underwent FoundationOne LiquidCDX comprehensive genomic profiling within 60 days before starting therapy were included. Clinical data was obtained from the nationwide deidentified Flatiron Health/Foundation Medicine Clinico-Genomic Database between 01/2011 and 12/2023.
resultsWe identified 778 patients for inclusion: 299 TF < 1% (TF-low), 175 TF 1-10% (TF-intermediate [int]), 304 TF > 10% (TF-high). Of these, 155 had BO-MBC, 622 had non-BO MBC (1 missing metastasis data). Among samples collected prior to first-line therapy (n = 256), there was no significant difference in the proportion of patients with detectable ctDNA comparing BO-MBC to non-BO MBC patients (P = 1.0). TF was prognostic among patients with BO-MBC: TF-low demonstrated more favorable real-world overall survival (rwOS) relative to TF-int (hazard ratio [HR] 2.19, 95% confidence interval [CI] 1.1-4.35) and TF-high (HR 2.07, 95% CI 1.12-3.82; log-rank P = 0.027). Multivariable analyses confirmed the independent and additive association of TF and less favorable rwOS. In multivariable analyses evaluating clinicopathologic factors associated with TF, non-BO metastases were not associated with higher ctDNA TF.
conclusionBO-MBC patients are as likely as non-BO-MBC to have detectable ctDNA and TF remains prognostic among BO-MBC patients, with TF < 1% associated with significantly better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.